Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment - BioSpace

Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment  BioSpace

Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional ...



Comments

Post a Comment

Popular posts from this blog

Глушители. Приборы бесшумной стрельбы

Image
inherited kidney disease :: Article Creator Hyperuricemia Ups Chronic Kidney Disease Risk Even With No Genetic Predisposition Hyperuricemia increases the risk of developing chronic kidney disease (CKD), whether or not an individual is genetically predisposed to it, investigators reported at the American Society of Nephrology's Kidney Week 2023 meeting in Philadelphia, Pennsylvania. Yaerim Kim, MD, PhD, of the Keimyung University School of Medicine in Daegu, Korea, and colleagues conducted a genome-wide association study of mostly White individuals in the United Kingdom Biobank. From 459,155 samples, they identified 438,253 clinical data points and 4,307,940 single nucleotide polymorphisms. Polygenic risk scores positively correlated with CKD development. Hyperuricemia was significantly associated with 54% increased odds of CKD across the range of polygenic risk scores, especially in those with low genetic risk, the investigators reported. ...
Read more